Advanced Search

Congenital Adrenal Hyperplasia Stocks List

Symbol Grade Name % Change
MLND D Millendo Therapeutics, Inc. 2.71
BBIO B BridgeBio Pharma, Inc. 2.23
SPRB F Spruce Biosciences, Inc. 2.78
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Hyperplasia Adrenal Gland Disorders Anatomy Classic Congenital Adrenal Hyperplasia Organ Systems Achondroplasia Amyloid Amyloidosis Biopharmaceutical Cardiomyopathy Clinical Development Cushing's Syndrome Endocrine Disease Endocrine Diseases Endocrine Disorders Endocrine System Familial Amyloid Polyneuropathy Fibroblast Growth Factor Receptor Late Stage Biopharmaceutical Medicine

Related ETFs - A few ETFs which own one or more of the above listed Congenital Adrenal Hyperplasia stocks.

Symbol Grade Name Weight
IBBJ C Defiance Nasdaq Junior Biotechnology ETF 1.49
IBB C iShares Nasdaq Biotechnology Index Fund 1.0
XBI D SPDR Series Trust SPDR S&P Biotech ETF 0.99
BTEC C Principal Healthcare Innovators Index ETF 0.83
BBC C Virtus LifeSci Biotech Clinical Trials ETF 0.78
View all Congenital Adrenal Hyperplasia related ETFs...
Compare ETFs
  • Compare IBB to BBC
  • Compare IBBJ to BTEC
  • Compare IBBJ to XBI

    • Recent Signals

    Date Stock Signal Type
    2021-02-24 BBIO 50 DMA Support Bullish
    2021-02-24 BBIO Pocket Pivot Bullish Swing Setup
    2021-02-24 MLND 20 DMA Resistance Bearish
    2021-02-24 SPRB Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
    2021-02-24 SPRB Crossed Above 20 DMA Bullish
    2021-02-24 SPRB 50 DMA Resistance Bearish
    2021-02-24 SPRB MACD Bullish Signal Line Cross Bullish

    Recent News for Congenital Adrenal Hyperplasia Stocks

    Date Stock Title
    Feb 20 BBIO The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More
    Feb 19 BBIO BridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing
    Feb 19 BBIO BridgeBio Pharma initiates dosing in mid-stage muscular dystrophy trial
    Feb 19 BBIO BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
    Related Industries: Biotechnology
    Related Stock Lists: Hyperplasia Adrenal Gland Disorders Anatomy Classic Congenital Adrenal Hyperplasia Organ Systems Achondroplasia Amyloid Amyloidosis Biopharmaceutical Cardiomyopathy Clinical Development Cushing's Syndrome Endocrine Disease Endocrine Diseases Endocrine Disorders Endocrine System Familial Amyloid Polyneuropathy Fibroblast Growth Factor Receptor Late Stage Biopharmaceutical Medicine

    Browse All Tags